Endonovo Reports Positive Results in Critical Limb Ischemia Study Using Non-Invasive Medical Device
February 12 2018 - 9:51AM
InvestorsHub NewsWire
Los Angeles, CA -- February 12, 2018 -- InvestorsHub
NewsWire -- Endonovo Therapeutics, Inc. (OTCQB: ENDV)
("Endonovo" or the "Company"), a commercial-stage developer of
non-invasive wearable Electroceutical™ devices, today announced
positive results from a study of critical limb ischemia (CLI) in
mice.
Animals treated three times per day with the Company's Pulsed
Electromagnetic Fields (PEMF) device had significantly higher blood
flow (ratio of blood flow of the ischemic limb to blood flow of
non-ischemic limb) at day 7 and 14 (57% and 71%, versus 36% and
52%) versus the controls. Furthermore, animals treated with PEMF
three times per day had significantly improved foot movement scores
and less tissue damage in the ischemic hind limb versus the
controls.
Critical Limb Ischemia (CLI) is an advanced stage of Peripheral
Artery Disease (PAD), a common vascular disease that affects
approximately 200 million people worldwide, where fatty deposits
block arteries in the legs, leading to pain, non-healing ulcers,
and gangrene. Worldwide, approximately 22-30 million people suffer
from CLI, according to The Sage Group. Patients with CLI have a
high risk of amputation and death, and patients unsuitable for
revascularization are left with no adequate treatment options.
Endonovo Therapeutics is currently developing a pipeline of
non-invasive medical devices, Electroceuticals™, for the treatment
of vascular diseases, including cardiovascular and cerebrovascular
disease. The Company's Pulsed Electromagnetic Fields (PEMF)
technology has been evaluated in a pilot clinical trial in 30
patients with ischemic cardiomyopathy and failed medical therapy
and revascularization options ("no option patients"). Patients in
the active cohort demonstrated significant improvements in
function, including improved Seattle Angina Questionnaire (SAQ)
subscales for Anginal Frequency and severity, and Physical
Activity. Furthermore, 3 patients in the active cohort had a 12-25%
increase in perfusion compared to the sham group.
"We believe our non-invasive medical devices will address
significantly unmet medical needs in vascular diseases, including
peripheral artery, cardiovascular and cerebrovascular disease,"
said Endonovo CEO, Alan Collier.
"Currently up to 40% of patients with critical limb ischemia are
not eligible for revascularization and have a high risk of
amputation and death within one year of being diagnosed. Our
Electroceuticals have demonstrated remarkable results in both
animal models and clinical trials in reducing inflammation,
improving blood flow and reducing tissue damage, which we believe
will save and improve lives, as well as reduce the economic burden
of these major diseases," concluded Mr. Collier.
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a commercial-stage developer of
non-invasive wearable Electroceuticals™. The Company's current
portfolio of commercial and clinical-stage wearable
Electroceuticals™ addresses wound healing, pain, post surgical
edema and Central Nervous System (CNS) Disorders, including
traumatic brain injury (TBI), acute concussions, post-concussion
syndrome and multiple sclerosis. The Company's non-invasive
Electroceutical™ device using pulsed short-wave radiofrequency at
27.12 MHz has been FDA-Cleared and CE Marked for the palliative
treatment of soft tissue injuries and post-operative pain and
edema, and has CMS National Coverage for the treatment of chronic
wounds. The Company's current portfolio of pre-clinical stage
Electroceuticals™ addresses chronic kidney disease, liver disease,
cardiovascular and peripheral artery disease. The Company's
non-invasive, wearable Electroceuticals™ work by restoring key
electrochemical processes that initiate anti-inflammatory and
growth factor cascades necessary for healing to occur.
Safe Harbor Statement
This press release contains information that constitutes
forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
All statements, trends, analysis, and other information contained
in this press release including words such as "anticipate,"
"believe," "plan," "estimate," "expect," "intend," and other
similar expressions of opinion, constitute forward-looking
statements. Any such forward-looking statements involve risks and
uncertainties that could cause actual results to differ materially
from any future results described within the forward-looking
statements. Risk factors that could contribute to such differences
include those matters more fully disclosed in the Company's reports
filed with the Securities and Exchange Commission. The
forward-looking information provided herein represents the
Company's estimates as of the date of the press release, and
subsequent events and developments may cause the Company's
estimates to change. The Company specifically disclaims any
obligation to update the forward-looking information in the future.
Therefore, this forward-looking information should not be relied
upon as representing the Company's estimates of its future
financial performance as of any date subsequent to the date of this
press release.
Investor Relations Contact:Endonovo Therapeutics, Inc.Mr. Steven BarnesSenior Vice President of Investor Relations(800) 701-1223, Ext. 108Sbarnes@endonovo.comwww.endonovo.comInvestors: Sign Up for Email Alerts on Endonovo